Spinal Muscular Atrophy

FSMA, genetics company, open screening capabilities to third-party compounds

Published in Gene Therapy Weekly, February 5th, 2004

Families of Spinal Muscular Atrophy (FSMA), an organization founded to promote research leading to effective treatment of spinal muscular atrophy (SMA), a debilitating and often fatal disease, announced the next step in its partnership with deCODE genetics (DCGN).

FSMA and deCODE are making available deCODE's high-throughput screening capabilities to test promising compounds that may increase SMN (survival motor neuron) levels or supplement SMN function.

Using compounds identified through previous FSMA-funded research, deCODE's Chicago, Illinois-based pharmaceuticals group has completed initial screening and is now working to optimize hits to obtain...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2004-02-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry